Pharmaceutical interventions arising from the review of pharmacotherapy in hospital patients with COVID-19
DOI:
https://doi.org/10.1590/Keywords:
COVID-19, SARS-CoV-2 virus, Clinical pharmacy, Pharmaceutical care, Pharmaceutical servicesAbstract
To characterize the main pharmaceutical interventions performed by reviewing the pharmacotherapy of hospital patients with COVID-19. This is a study carried out in a hospital center in the northern region of Santa Catarina, in which data were collected on pharmaceutical interventions resulting from the review of the pharmacotherapy of hospital patients with COVID-19, between April 2020 and June 2021. During the study period, a total of 16,675 medical presciptions were validated by pharmacists in theselected hospitalization sectors. These validations resulted in 1,108 pharmaceutical interventions, with the largest number related to drug dose adjustment (25.9%). Among the drugs, the class with the highest number of interventions was antimicrobials, especially Azithromycin with 23.5% of interventions performed, followed by Teicoplanin 23.9% and Meropenem 18.6%. Pharmaceutical interventions due to kidney function were also highlighted, as the disease is not restricted to damage to the respiratory system, but also presents complications in other organs, such as the kidneys. Through the review of pharmacotherapy and the pharmaceutical interventions resulting from this activity, clinical pharmacists played a key role in optimizing pharmacotherapy, in addition to promoting the safe use of medications.
Downloads
References
Al-Quteimat OM, Amer AM. SARS-CoV-2 outbreak: How can pharmacists help? Res Social Adm Pharm. 2020; 17: 480-482.
Araujo EO, Viapiana M, Domingues EAM, Oliveira GS, Polisel CG. Pharmaceutical interventions in an intensive care unit at a university hospital. Rev Bras Farm Hosp Serv Saude. 2017; 8: 25-30.
Brazil. Federal Pharmacy Council. Resolution no. 585, of August 29, 2013. Amendment: Regulates the clinical attributions of pharmacists and makes other provisions [S. l.], 11p. 29 Aug. 2013.
Brazil. Ministry of Health. Recommendation report: Clinical Protocols and Therapeutic Guidelines: Brazilian Guidelines for Hospital Treatment of Patients with COVID-19 - Chapter 2: Drug Treatment. CONITEC. Brasilia (DF), n. 638, 111p., 2021.
Brazilian Society of Hospital Pharmacy, compiler. Minimum Standards for Hospital Pharmacy. 3ed. São Paulo: 2017. 40 p.
Bruniera FR, Ferreira FM, Saviolli LRM, Bacci MR, Feder D, Pedreira MLG. The use of vancomycin with its therapeutic and adverse effects: a review. Eur Rev Med Pharmacol Sci. 2015; 19: 694-700.
Cardinal LSM, Fernandes CS. Pharmaceutical intervention in the prescription validation process. Rev Bras Farm Hosp Serv Saude. 2014; 5: 14-19.
Carvalho DCMF. Clinical Pharmacy and Patient Care Manual [bibliography]. 1ed. Rio de Janeiro: Atheneu; 2017. 303 p.
Carvalho LF, Paula TCGQ, Peixoto VS. Acute kidney injury in patients diagnosed with COVID-19 in an ICU in southwestern Goiás. RSD. 2021; 10: 1-9.
Ciraque A, Silva CCS, Silva AS. Drug-induced nephrotoxicity. Rev Terra & Cult, 2022.38: 35-51.
Duarte PMA, Filho FAGB, Duarte JVA, Duarte BA, Duarte IA, Lemes RPG, et al. Application of the FASTHUG- MAIDENS mnemonic and evaluation of its impact on pharmaceutical interventions in an adult intensive care unit. Rev Assoc Med Bras. 2020; 10(66): 1335-1337.
Falavigna M, Colpani V, Stein C, Azevedo LCP, Bagattini AM, Brito GV, et al. Guidelines for the pharmacological treatment of COVID-19. The task-force/consensus guideline of the Brazilian Association of Intensive Care Medicine, the Brazilian Society of Infectious Diseases and the Brazilian Society of Pulmonology and Tisiology. Rev Bras Ter Intensiva. 2020; 32: 166-196.
Farias TF, Aguiar KS, Rotta I, Belletti KMS, Carlotto J. Implementation of a clinical pharmaceutical service in hematology. Einstein. 2016; 14: 384-390.
Fortaleza CMCB, Padoveze MC, Kiffer CRV, Barth AL, Carneiro ICRS, Giamberardino H I G, et al. Multi-state survey of healthcare-associated infections in acute care hospitals in Brazil. J Hosp Infect. 2017; 96: 139-144.
Furtado RHM, Berwanger O, Fonseca HA, Corrêa TD, Ferraz LR, Lapa MG, et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet. 2020; 396: 959–967.
Gilbert DN, Chambers HF, Saag MS, Pavia AT, Boucher HW, Black D, et al. The Sanford Guide: To Antimicrobial Therapy.52th ed. Sperryville, Virginia: INC; 2022. 341 p. ISBN: 978-1-944272-20-3.
Hatah E, Braund R, Tordoff J, Duffull S B. A systematic review and meta-analysis of pharmacist-led fee-for-services medication review. BJCP. 2013; 77: 102-115.
Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021; 384: 693-704.
Hua X, Gu M, Zeng F, Hu H, Zhou T, Zhang Y, et al. Pharmacy administration and pharmaceutical care practice in a module hospital during the COVID-19 epidemic. J Am Pharm Assoc.2020; 60: 431-438.
Joinville. Annual Management Report (RAG) 2021. Strategic management and articulation of the network [Internet]. 2022. [cited 2023 Jan 31]; Available from: https://www.joinville.sc.gov.br/publicacoes/relatorios-anuais-de-gestao-em- saude-do-municipio-de-joinville/
» https://www.joinville.sc.gov.br/publicacoes/relatorios-anuais-de-gestao-em-
Joinville. Secretariat of Health (SES) and Secretariat of Communication (SECOM). COVID-19 cases in Joinville (COVID-19 Panel) [Internet]. 2023. [cited 2023 Jan 31]; Available from: https://www.joinville.sc.gov.br/publicacoes/relatorios-anuais-de-gestao-em-saude-do-municipio-dejoinville/
Lima B S S, Gomes A C R, Santos M E A, Gripp M R, Lima V P. Results of the profile of antibiotic use in covid intensive care units, non-covid intensive care units and covid wards using the prevalence point analysis method during 2020. Braz J Infect Dis. 2022; 26.
Lima Í M, Vidigal S B, Lima N M, Carvalho D A, Santos E J, Junior A C, et al. Application of the FASTHUG-MAIDENS mnemonic and evaluation of its impact on pharmaceutical interventions in an adult intensive care unit. Rev Bras Farm Hosp Serv Saude.2021; 12: 1-9.
Lynch M, O’Leary A C. COVID-19 related regulatory change for pharmacists - The case for its retention post the pandemic. Res Social Adm Pharm. 2020; 17: 1913-1919.
Mallhi TH, Liaqat A, Abid A, Khane YH, Alotaibi, Nasser H, Alzarea AI, et al. Multilevel Engagements of Pharmacists During the COVID-19 Pandemic: Front Public Health.2020; 8: 1-14.
Martins MAP, Medeiros AFA, Almeida CDC, Reis AMM. Preparedness of pharmacists to respond to the emergency of the COVID-19 pandemic in Brazil: a comprehensive overview. Drugs Ther Perspect.2020; 36: 455-462.
Mas-Font S, Ros-Martinez J, Pérez-Calvo C, Villa-Díaz P, Aldunate-Calvo S, Moreno-Clari E, et al. Prevention of acute kidney injury in Intensive Care Units. Med. Intensiva. 2017; 41: 116-126.
Mercado MG, Smith DK, Guard EL. Acute Kidney Injury: Diagnosis and Management. Am Fam Physician.2019; 100: 687-694.
Oliveira SJV, Santiago MAA, Lisboa LFT, Grisólia DPA, Costa CMM, Grisólia ABA. The role of pharmacists in promoting the rational use of antibiotics in hospital settings: An integrative review. Research, Society and Development [Internet]. 2023 [cited 2024 Jan 2]; 12 DOI 0.33448/rsd-v12i11.43608. Available from: https://rsdjournal.org/index.php/rsd/article/view/43608
» https://rsdjournal.org/index.php/rsd/article/view/43608
Pasetti ES, Caiana ABS, Ribeiro KO, Freitas EL, Gomes ECS, Pereira LGS, et al. Etiology and antimicrobial sensitivity profile of ventilator-associated pneumonia (VAP) during the covid-19 pandemic in a hospital in the greater abc paulista region. Braz J Infect Dis.2022; 26: 1.
Pharmaceutical Care Network Europe. Classification for drug related problem [Internet]. 2019 [cited 2024 Jan 3]; 9. Available from: https://www.pcne.org/upload/files/334_PCNE_classification_V9-0.pdf
» https://www.pcne.org/upload/files/334_PCNE_classification_V9-0.pdf
Rahn B, Zonzini FH, Mendes AM. Review of in-hospital pharmacotherapy: risk and network analysis. Rev Bras Farm Hosp Serv Saude [Internet]. 2023 [cited 2024 Jan 3]; 14 DOI 10.30968/rbfhss.2023.144.0995. Available from: https://rbfhss.org.br/sbrafh
» https://doi.org/10.30968/rbfhss.2023.144.0995
» https://rbfhss.org.br/sbrafh
Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, et al. Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing. Clin Infect Dis.2020; 71: 2459–2468.
Rêgo MM, Comarella L. The role of pharmaceutical analysis of hospital prescriptions. Caderno Saúde e Desenvolvimento. 2015.7: 17-31.
Santos KC, Barbosa, MJ, Araújo WNMS, Sena VV, Souza T. The Role of Clinical and Hospital Pharmacy in Managing the Use of Antimicrobials in a Public Hospital in the Federal District. Revista de Divulgação Científica Sena Aires.2019; 8(2): 153-159.
Silva JG, Pimentel AF, Teixeira CA. Analysis of pharmaceutical interventions in a COVID-19 intensive care unit at a university hospital in Rio de Janeiro. Rev Bras Farm Hosp Serv Saude.2022; 13: 1-9.
Tarighi P, Eftekhari S, Chizari M, Sabernavaei M, Jafari D, Mirzabeigi P. A review of potential suggested drugs for coronavirus disease (COVID-19) treatment. Eur J Pharmacol. 2021; 895. DOI 10.1016/j.ejphar.2021.173890. Available from: https://pubmed.ncbi.nlm.nih.gov/33482181/
» https://doi.org/10.1016/j.ejphar.2021.173890.
» https://pubmed.ncbi.nlm.nih.gov/33482181/
Trissel L. A. Handbook on Injetable. Drugs. 18º ed. Bethesda: American Society of Health – System Pharmacists; 2015.
Unimed Joinville Hospital Center. Pharmaceutical Assistance Policy. 39062th ed. Joinville: [publisher unknown]; 2021. 1-15 p. 2.00 vol.
Visacri MB, Figueiredo IV, Lima TM. Role of pharmacist during the COVID-19 pandemic: A scoping review. Res Social Adm Pharm.2021; 17: 1799-1806.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on-line journal has open and free access.
